Crossingbridge Advisors
DMAA icon

Crossingbridge Advisors’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Crossingbridge Advisors’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.08M Buy
+374,866
New +$4.03M 0.71% 56
2025
Q2 		– Sell
-850,000
Closed -$1.3M – 114
2025
Q1 		$1.3M Buy
+850,000
New +$8.5M 0.68% 31

Other funds holding DMAA

Mizuho Securities USA
Mizuho Securities USA New York $6.3B AUM 30.7% 1-Year Est. Return
Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.34B AUM 3.39% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return
First Trust Capital Management
First Trust Capital Management Chicago, Illinois $2.08B AUM 59.2% 1-Year Est. Return
Westchester Capital Management (New York)
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 22.91% 1-Year Est. Return
RLH Capital
RLH Capital Great Neck, New York $277M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Dakota Wealth Management
Dakota Wealth Management Palm Beach Gardens, Florida $5.38B AUM 27.63% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return

Crossingbridge Advisors's DMAA Position: Q3 2026 in Review

Crossingbridge Advisors opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q3 2026: 374,866 shares worth $4.08M. The stake represents 0.71% of the portfolio and ranks #56 among its holdings. This is a return to the name: Crossingbridge Advisors previously reported a position in DMAA as recently as Q1 2025.

Crossingbridge Advisors first reported a position in DMAA in Q1 2025 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold DMAA as of Q3 2026.

  • Crossingbridge Advisors held 374,866 shares of Drugs Made In America Acquisition Corp worth $4.08M as of Q3 2026.
  • Drugs Made In America Acquisition Corp was a new Crossingbridge Advisors position in Q3 2026.
  • Drugs Made In America Acquisition Corp made up 0.71% of Crossingbridge Advisors's portfolio in Q3 2026, its #56 holding.
  • Crossingbridge Advisors first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2026.

Based on Crossingbridge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.